Marcelle Cedars, MD

Director, Center for Reproductive Health

Dr. Marcelle Cedars is the director of the UCSF Center for Reproductive Health, and is a clinical specialist in the fields of in vitro fertilization, perimenopause and polycystic ovarian ovary syndrome (PCOS). As director of the Division of Reproductive Endocrinology, she coordinates the relationship between science and research being done at UCSF and personalized care for medical center patients.

Cedars received her medical training at the University of Texas Southwestern School of Medicine, completed her residency in obstetrics and gynecology at Parkland Memorial Hospital in Dallas, and did her fellowship in reproductive endocrinology at UCLA.

Clinics

Center for Reproductive Health at Mission Bay
499 Illinois St., Sixth Floor
San Francisco, CA 94158
Phone: (415) 353-7475
Fax: (415) 353-7744

Hours: Monday to Friday
8 a.m. – 4:45 p.m.
Saturday and Sunday apts. available for patients undergoing treatment

Center for Reproductive Health at Mount Zion
2356 Sutter St., Seventh Floor
San Francisco, CA 94115
Phone: (415) 353-7475
Fax: (415) 353-7744

Hours: Monday to Friday
8 a.m. – 4:45 p.m.
Saturday and Sunday apts. available for patients undergoing treatment

PCOS Clinic
499 Illinois St.
San Francisco, CA 94158
Phone: (415) 885-3674
Fax: (415) 353-7744

Hours: Two Thursdays a month
8 a.m. – 5 p.m.

Conditions & Treatments

Academic Title

Professor

More about Marcelle Cedars

Education

University of Texas, Southwestern School of Medicine 1981

Residencies

Parkland Hospital, OB/GYN 1982

Fellowships

Parkland Hospital, OB/GYN 1985
UCLA Medical Center, Reproductive Endocrinology 1987

Selected Research and Publications

  1. Aghajanova L, Cedars MI, Huddleston HG. Platelet-rich plasma in the management of Asherman syndrome: case report. J Assist Reprod Genet. 2018 Feb 17.
  2. Ahmad AK, Kao CN, Quinn M, Lenhart N, Rosen M, Cedars MI, Huddleston H. Differential rate in decline in ovarian reserve markers in women with polycystic ovary syndrome compared with control subjects: results of a longitudinal study. Fertil Steril. 2018 Mar; 109(3):526-531.
  3. Anaya Y, Mata DA, Letourneau J, Cakmak H, Cedars MI, Rosen MP. Author Correction: A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols. J Assist Reprod Genet. 2018 Feb; 35(2):309.
  4. Graves JS, Henry RG, Cree BAC, Lambert-Messerlian G, Greenblatt RM, Waubant E, Cedars MI, Zhu A. Ovarian aging is associated with gray matter volume and disability in women with MS. Neurology. 2018 Jan 16; 90(3):e254-e260.
  5. Greenwood EA, Cedars MI, Santoro N, Eisenberg E, Kao CN, Haisenleder DJ, Diamond MP, Huddleston HG. Antimüllerian hormone levels and antral follicle counts are not reduced compared with community controls in patients with rigorously defined unexplained infertility. Fertil Steril. 2017 12; 108(6):1070-1077.
  6. Huddleston HG, Quinn MM, Kao CN, Lenhart N, Rosen MP, Cedars MI. Women with polycystic ovary syndrome demonstrate worsening markers of cardiovascular risk over the short-term despite declining hyperandrogenaemia: Results of a longitudinal study with community controls. Clin Endocrinol (Oxf). 2017 Dec; 87(6):775-782.
  7. Anaya Y, Mata DA, Letourneau J, Cakmak H, Cedars MI, Rosen MP. A novel oocyte maturation trigger using 1500 IU of human chorionic gonadotropin plus 450 IU of follicle-stimulating hormone may decrease ovarian hyperstimulation syndrome across all in vitro fertilization stimulation protocols. J Assist Reprod Genet. 2018 Feb; 35(2):297-307.
  8. Taylor HS, Tal A, Pal L, Li F, Black DM, Brinton EA, Budoff MJ, Cedars MI, Du W, Hodis HN, Lobo RA, Manson JE, Merriam GR, Miller VM, Naftolin F, Neal-Perry G, Santoro NF, Harman SM. Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS). JAMA Intern Med. 2017 Oct 01; 177(10):1471-1479.
  9. Herndon CN, Anaya Y, Noel M, Cakmak H, Cedars MI. Outcomes from a university-based low-cost in vitro fertilization program providing access to care for a low-resource socioculturally diverse urban community. Fertil Steril. 2017 10; 108(4):642-649.e4.
  10. Quinn MM, Kao CN, Ahmad AK, Haisenleder DJ, Santoro N, Eisenberg E, Legro RS, Cedars MI, Huddleston HG. Age-stratified thresholds of anti-Müllerian hormone improve prediction of polycystic ovary syndrome over a population-based threshold. Clin Endocrinol (Oxf). 2017 Dec; 87(6):733-740.
  11. Schmidt TH, Okhovat JP, Khanijow K, Huddleston H, Cedars M, Pasch L, Wang ET, Lee J, Shinkai K. Rotterdam criteria-based diagnostic subtype is not a strong predictor of cutaneous phenotype in patients with polycystic ovary syndrome: A cross-sectional study. J Am Acad Dermatol. 2017 07; 77(1):174-176.
  12. Quinn MM, Cedars MI. A Canary in the Coal Mine: Reproductive Health and Cardiovascular Disease in Women. Semin Reprod Med. 2017 05; 35(3):250-255.
  13. Reid SP, Kao CN, Pasch L, Shinkai K, Cedars MI, Huddleston HG. Ovarian morphology is associated with insulin resistance in women with polycystic ovary syndrome: a cross sectional study. Fertil Res Pract. 2017; 3:8.
  14. Sarkar M, Wellons M, Cedars MI, VanWagner L, Gunderson EP, Ajmera V, Torchen L, Siscovick D, Carr JJ, Terry JG, Rinella M, Lewis CE, Terrault N. Testosterone Levels in Pre-Menopausal Women are Associated With Nonalcoholic Fatty Liver Disease in Midlife. Am J Gastroenterol. 2017 May; 112(5):755-762.
  15. Afifi L, Saeed L, Pasch LA, Huddleston HG, Cedars MI, Zane LT, Shinkai K. Association of ethnicity, Fitzpatrick skin type, and hirsutism: A retrospective cross-sectional study of women with polycystic ovarian syndrome. Int J Womens Dermatol. 2017 Mar; 3(1):37-43.
  16. Salem WH, Letourneau JM, Chan J, Chan SW, Cedars M, Rosen MP. Cancer survivors of gynecologic malignancies are at risk for decreased opportunity for fertility preservation. Contracept Reprod Med. 2017; 2:12.
  17. Santoro N, Allshouse A, Neal-Perry G, Pal L, Lobo RA, Naftolin F, Black DM, Brinton EA, Budoff MJ, Cedars MI, Dowling NM, Dunn M, Gleason CE, Hodis HN, Isaac B, Magnani M, Manson JE, Miller VM, Taylor HS, Wharton W, Wolff E, Zepeda V, Harman SM. Longitudinal changes in menopausal symptoms comparing women randomized to low-dose oral conjugated estrogens or transdermal estradiol plus micronized progesterone versus placebo: the Kronos Early Estrogen Prevention Study. Menopause. 2017 Mar; 24(3):238-246.
  18. Quinn MM, Cakmak H, Letourneau JM, Cedars MI, Rosen MP. Response to ovarian stimulation is not impacted by a breast cancer diagnosis. Hum Reprod. 2017 03 01; 32(3):568-574.
  19. Quinn MM, Kao CN, Ahmad A, Lenhart N, Shinkai K, Cedars MI, Huddleston HG. Raising threshold for diagnosis of polycystic ovary syndrome excludes population of patients with metabolic risk. Fertil Steril. 2016 Oct; 106(5):1244-1251.
  20. Pasch L, He SY, Huddleston H, Cedars MI, Beshay A, Zane LT, Shinkai K. Clinician vs Self-ratings of Hirsutism in Patients With Polycystic Ovarian Syndrome: Associations With Quality of Life and Depression. JAMA Dermatol. 2016 07 01; 152(7):783-8.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.